The Week Ahead: COS...
Health Care: Drugs
Novartis AG (NVS: NYSE)
$74.36 0.54 | 0.73%
05/24/13 - 04:02 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 9.62B | 9.24B | 9.97B | 8.45B |
| Operating Gains/Losses | 0.00 | 404.00M | 571.00M | 762.00M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | -732.00M | 0.00 | -934.00M |
| (Increase) Decrease in Inventories | 0.00 | 45.00M | 0.00 | 237.00M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 0.00 | 195.00M | 0.00 | 512.00M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | -140.00M | 379.00M | 1.76B | 873.00M |
| Other Non-Cash Items | 6.74B | 7.21B | 4.38B | 1.04B |
| Net Cash From Continuing Operations | 14.19B | 14.31B | 14.07B | 12.19B |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 14.19B | 14.31B | 14.07B | 12.19B |
| Sale of Property, Plant & Equipment | 255.00M | 704.00M | 581.00M | 99.00M |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 516.00M | 3.34B | 53.20B | 0.00 |
| Purchases of Property, Plant & Equipment | -3.07B | -2.39B | -2.23B | -2.73B |
| Acquisitions | -1.74B | -581.00M | -26.67B | -925.00M |
| Purchases of Short-Term Investments | -1.64B | -1.75B | -40.57B | -14.10B |
| Other Cash from Investing Activities | -39.00M | 0.00 | 69.00M | -81.00M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -5.68B | -792.00M | -15.76B | -14.22B |
| Issuance of Debt | 1.98B | 281.00M | 8.28B | 7.05B |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 414.00M | 163.00M | 730.00M | 724.00M |
| Repayment of Long-Term Debt | -2.44B | -3.08B | -5.00M | -22.00M |
| Repurchase of Capital Stock | -505.00M | -3.63B | -311.00M | -461.00M |
| Payment of Cash Dividends | -6.12B | -5.57B | -4.58B | -3.99B |
| Other Financing Charges, Net | -6.00M | -3.19B | 0.00 | -491.00M |
| Net Cash From Financing Activities | -6.68B | -15.02B | 4.12B | 2.81B |
| Effect of Exchange Rate Changes | -1.00M | -103.00M | -2.00M | 75.00M |
| Net Change in Cash & Cash Equivalents | 1.84B | -1.61B | 2.42B | 856.00M |
Portfolios with NVS
- Portfolio NameUser Type
- Contributor9 Stocks to Buy for a Europ...
- Contributor8 High-Quality, Dividend-Pa...
- Userjohns7 Portfolio 1
- UserGFNN Stockdiagnostics 8
- ContributorTechnical Setups for the We...
- UserKAREL VON ZOETE
- UserMARIA DEL HUERTO
- ContributorHighest-Yielding Drug Stocks
- Userretirement
- ContributorLarge-Cap Dividend Stocks t...
Latest NVS Headlines from TheStreet
- Novartis AG Stock Buy Recommendation Reiterated (NVS) 05.24.13 | 10:05 am
- 3 Stocks Dragging In The Drugs Industry 05.23.13 | 01:05 pm
- Ireland Welcomes Watson Pharmaceuticals, an American Success 05.20.13 | 02:05 pm
- Novartis AG (NVS): Today's Featured Drugs Laggard 05.17.13 | 05:05 pm
- Morning Briefing: 10 Things You Should Know 05.16.13 | 07:05 am
- Novartis Reaches New 52-Week High (NVS) 05.15.13 | 10:05 am
- Aveo Screwed Up But Its Kidney Cancer Drug Is Real 05.15.13 | 08:05 am
- Novartis AG (NVS): Today's Featured Drugs Laggard 05.09.13 | 05:05 pm
- Today's Stocks Driving Success For The Health Care Sector 05.08.13 | 01:05 pm
- Novartis Reaches New 52-Week High (NVS) 05.08.13 | 09:05 am
Press Releases for NVS
- Malaria No More Announces Innovative Partners For Its 'Power Of One' Malaria Campaign - PR Newswire 04.25.13 | 09:04 am
- University Teams Tap Mobile Phones And Social Networks To Fight Non-communicable Diseases - PR Newswire 02.09.12 | 04:02 pm
- IBM Launches University Competition To Combat Growth Of Non-Communicable Diseases - PR Newswire 10.07.11 | 03:10 pm
- ITG Healthcare Market Research Study Finds XGEVA On Track To Be Top-Prescribed Drug For Prevention Of SREs In Cancer Patients - PR Newswire 07.28.11 | 08:07 am
- ITG's Majestic Market Research Prostate Cancer Study Indicates Amgen's Xgeva Is Poised To Steal Significant Share From Novartis' Zometa; Physicians Still On The Fence About Dendreon's Provenge - PR Newswire 03.22.11 | 04:03 pm
Partner Headlines for NVS
- J&J Q1 Earnings Beat; Pharma Strong, Devices Weak - Investor's Business Daily 04.16.13 | 04:04 pm
- Four Dow Components Due for a Dividend Hike (CVX, XOM, IBM, JNJ) - Benzinga 04.04.13 | 12:04 pm
- Curing Parkinson's: The Alternative Approach - Is There Money To Be Made? - Seeking Alpha 04.04.13 | 09:04 am
- Will Novartis’s India Setback Bother These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.01.13 | 12:04 pm
- Will Novartis’s India Setback Bother These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.01.13 | 12:04 pm
- Analysts: CBS to Gain From Sports Ratings and 4 New Opinions Investors Must Take Note Of - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Analysts: CBS to Gain From Sports Ratings and 4 New Opinions Investors Must Take Note Of - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Will This Court Decision Be a Thorn in the Side of Novartis? - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Will This Court Decision Be a Thorn in the Side of Novartis? - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
